Premium
Pulmonary surfactant protein a in pleural effusions
Author(s) -
Shijubo Noriharu,
Tsutahara Shin,
Hirasawa Michio,
Takahashi Hiroki,
Honda Yasuhito,
Suzuki Akira,
Kuroki Yoshio,
Akino Toyoaki
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920615)69:12<2905::aid-cncr2820691207>3.0.co;2-l
Subject(s) - medicine , lung , pathology , lung cancer , adenocarcinoma , surfactant protein a , pleurisy , respiratory disease , carcinoma , pulmonary surfactant , pleural disease , pleural effusion , cancer , biology , biochemistry
Abstract Pulmonary surfactant protein A (SP‐A) is known to be a major phospholipid‐associated glycoprotein in pulmonary surfactant, which is specific to the lung. Immunohis‐tochemically, expression of SP‐A in tumor tissues is found in approximately 50% of patients with lung adeno‐carcinoma but not in the other histologic types of lung cancer or metastatic lung tumors. In this study, the SP‐A content of pleural effusions was determined using an enzyme‐linked immunosorbent assay. These results showed that approximately 40% of patients with lung ad‐enocarcinomas (27 of 67) had high levels of SP‐A (> 500 ng/ml) in their pleural effusions. By contrast, patients with other histologic types of lung cancers, adenocarci‐nomas of different primary sites, and tuberculosis had low levels of SP‐A in their pleural effusions. The determination of SP‐A in malignant effusions will contribute to distinguishing primary lung adenocarcinoma from ade‐nocarcinomas of miscellaneous origin.